The Intuitive Case for β-blockers in Patients with ESRD
Article first published online: 24 JAN 2012
© 2012 Wiley Periodicals, Inc.
Seminars in Dialysis
Volume 25, Issue 1, pages 15–21, January/February 2012
How to Cite
McQuillan, R. F. and Chan, C. T. (2012), The Intuitive Case for β-blockers in Patients with ESRD. Seminars in Dialysis, 25: 15–21. doi: 10.1111/j.1525-139X.2011.01016.x
- Issue published online: 24 JAN 2012
- Article first published online: 24 JAN 2012
Sudden cardiac death (SCD) is common in dialysis patients accounting for up to 25% of all-cause mortality. Unlike in the general population, occlusive coronary artery disease is implicated in a minority of these deaths. Activation of the sympathetic nervous system is prevalent in the dialysis population and may underlie this high rate of SCD. β-blockers reduce SCD in the general population and, given their mode of action, β-blockers would seem to be an ideal class of agents to prevent SCD in dialysis patients. In this review, we will explore the etiology of SCD in dialysis patients and discuss the evidence supporting the use of β-blockers in patients with ESRD. We will also examine potential impediments to the use β-blocker in the dialysis population and outline directions for future trials in this area.